Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

Maitreyee K. Jathal(University of California, Davis), P. Ghosh(Unknown)
British Journal of Cancer
June 17, 2019
Cited by 23


Related Papers